

Results of Recent NRG Oncology Trials

8:00 AM	Welcome	Walter J. Curran, Jr., M.D. Philip DiSaia, M.D. Norman Wolmark, M.D.
8:05 AM	NRG Oncology Publications Committee Update	Deborah Bruner, RN, Ph.D.
8:15 AM	Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer. <i>American Society for Radiation Oncology 2014.</i>	Hak Choy, M.D.
8:35 AM	Randomized Phase 2 Evaluation of Bevacizumab versus Bevacizumab/Fosbretabulin in Recurrent Ovarian, Tubal or Peritoneal Carcinoma: an NRG Oncology/Gynecologic Oncology Group Study. <i>International Gynecologic Cancer Society Meeting 2014.</i>	Bradley J. Monk, M.D.
8:55 AM	The Effect on Overall and Disease-Free Survival by Adding Bevacizumab and/or Antimetabolites to Standard Neoadjuvant Chemotherapy: NSABP Protocol B-40. <i>San Antonio Breast Cancer Symposium 2014.</i>	Harry D. Bear, M.D., Ph.D.
9:15 AM	The Initial Report of Local Control on RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Treated without Surgery. <i>American Society for Radiation Oncology 2014.</i>	David H. Ilson, M.D., Ph.D.
9:35 AM	The KRAS-variant and Cetuximab Response in RTOG 0522. <i>American Society for Clinical Oncology 2014.</i>	Joanne Weidhaas, M.D, Ph.D.